Michael Sapienza: FDA Approves First Adjuvant Immunotherapy Regimen for Stage III dMMR Colorectal Cancer
Michael Sapienza: FDA Approves First Adjuvant Immunotherapy Regimen for Stage III dMMR Colorectal Cancer Oncodaily
Онкология
🎗️Лента новостей
🎗️
Онкология
New ADCs Poised for HER2-Low Advanced Breast Cancer Space as Enhertu Gathers Data in Earlier Setting
New ADCs Poised for HER2-Low Advanced Breast Cancer Space as Enhertu Gathers Data in Earlier Setting GenomeWeb
Онкология
Addressing Metabolic Dysregulation to Reduce Breast Cancer Disparities
Addressing Metabolic Dysregulation to Reduce Breast Cancer Disparities CancerNetwork
Онкология
AI map of bowel tumours reveals drug vulnerabilities in hardest-to-treat colorectal cancer
AI map of bowel tumours reveals drug vulnerabilities in hardest-to-treat colorectal cancer Bioengineer.org
Онкология
Ravindhi Murphy: DETERMINE Trial Reports 90% Objective Response Rate With Alectinib in Rare Cancers
Ravindhi Murphy: DETERMINE Trial Reports 90% Objective Response Rate With Alectinib in Rare Cancers Oncodaily
Онкология
Новый инструмент ИИ может прогнозировать выживаемость онкологических пациентов по одному селфи — исследование
Новый инструмент ИИ может прогнозировать выживаемость онкологических пациентов по одному селфи — исследование DELFI
Онкология
Lilly’s sofetabart mipitecan shows 79% response rate in platinum-sensitive ovarian cancer
Lilly’s sofetabart mipitecan shows 79% response rate in platinum-sensitive ovarian cancer The Clinical Trial Vanguard
Онкология
Рак на заказ: как для каждого пациента напечатают уникальную вакцину против меланомы - Поиск
Рак на заказ: как для каждого пациента напечатают уникальную вакцину против меланомы Поиск - новости науки и техники
Онкология
Perspective Therapeutics’ [212Pb]VMT-α-NET shows responses in neuroendocrine tumor trial
Perspective Therapeutics’ [212Pb]VMT-α-NET shows responses in neuroendocrine tumor trial The Clinical Trial Vanguard
Онкология
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen
Онкология
Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase III Trial
Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase III Trial Inside Precision Medicine
Онкология
‘Practice-changing’ new lung cancer immunotherapy improves survival
‘Practice-changing’ new lung cancer immunotherapy improves survival NBC News